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new ligands. Newer approaches aim to dissect the re-
quirements for each step of antigen processing—that
is, proteasome cleavage specificity, TAP specificity,
and MHC binding specificity (reviewed in Stevanovic
[2005]). Such approaches should now consider ERAAP
activity on MHC-bound peptides when determining
criteria for epitope generation.
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695Human Tyk2 Kinase Deficiency:
Another Primary
Immunodeficiency Syndrome
Janus kinases are critical for cytokine signaling. Muta-
tions of Jak3 cause primary immunodeficiency, but
Minegishi et al. (2006) now show that mutation of an-
other Jak, tyrosine kinase 2, underlies another human
immunodeficiency syndrome.
Cytokines regulate immune-cell development, homeo-
stasis, differentiation, and effector function; as such,
they have critical roles in host defense and in the path-
ogenesis of autoimmune and autoinflammatory disor-
ders. A large subset of cytokine receptors (type I and
II cytokine receptors) lack intrinsic kinase activity, but
instead rely on a small family of receptor-associated
cytoplasmic tyrosine kinases to initiate signaling. This
family, known as Janus kinases or Jaks, consists of only
four members, Jaks1–3 and tyrosine kinase 2 (Tyk2).
The essential function of Jaks in effecting cytokine sig-
nals has been substantiated by various approaches and
is underscored by the fact that Jak3 mutations result in
severe combined immunodeficiency (SCID) in humans.
Other Jaks were not previously associated with primary
immunodeficiency in humans, but Tyk2 can now be
added to the list. Minegishi et al. (2006) have identified
a patient with Tyk2 deficiency who exhibited broader
and more profound immunological defects than would
be anticipated from studies of Tyk22/2mice. The signal-
ing defects resulted in a complex clinical picture that
included Hyper IgE Syndrome (HIES) and susceptibility
to multiple infectious pathogens.Jaks constitutively associate with the cytoplasmic
domains of type I and II cytokine receptors and, upon
ligand binding, phosphorylate receptor subunits. This
serves to recruit signal transducers and activators of
transcription (Stats) and other adapters and signaling
molecules. Jaks also phosphorylate and activate Stats,
promoting nuclear translocation and transcription. The
connection between Jaks and cytokine signaling was
first revealed when a screen for genes involved in type
I interferon (IFN) signaling identified Tyk2 as an essen-
tial element (Velazquez et al., 1992). Shortly thereafter,
through the use of somatic mutant cell lines, the first de-
fined connections between different cytokine receptors
and different Jaks and Stats were made (Darnell et al.,
1994). In vitro stimulations also paired different Jaks
with apparent activating cytokines.
The first in vivo proof that Jaks are critical for cytokine
signaling came from studies of a group of human disor-
ders termed SCID. Jak3 selectively associates with the
common g cytokine receptor chain (gc), and mutations
in gc were known to cause SCID (X-SCID). Mutations
of JAK3 were therefore sought and found to underlie
some cases of autosomal recessive SCID (Macchi
et al., 1995); a similar phenotype was also observed in
Jak3-deficient mice. Several years later, Jak1- and
Jak2-deficient mice were produced, but it was not until
2000 that Tyk2-deficient mice were generated (Kara-
ghiosoff et al., 2000; Shimoda et al., 2000). In contrast
to Jak3, which appears to associate with only one re-
ceptor subunit, Tyk2 is activated by an array of cytokine
receptors. It was therefore striking that Tyk2 deficiency
in mice identified somewhat limited roles for this kinase,
primarily in interleukin 12 (IL-12) and interferon (IFN-)
a and b signaling.
In a compelling new study, Minegishi et al. (2006)
identified a patient homozygous for a TYK2 mutation
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696Figure 1. Cytokines and Receptors that Utilize Tyk2
Minegishi et al. (2006) show that Tyk2 has broader and more profound functions in humans than previously appreciated on the basis of analysis of
murine models. Murine models indicate that Tyk2 functions primarily in IL-12 and type I IFN signaling. However, the current study shows that in
addition to IFN-a and -b and IL-12 signaling, Tyk2 has major effects on the transduction of IL-23, IL-10, and IL-6 signals. Because IL-6 signals
through the gp130 receptor chain that is common to a large family of cytokines, including IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM), ciliary
neurotrophic factor, cardiotrophin-1, cardiotrophin-like cytokine, and leukemia inhibitory factor (LIF), Tyk2 might also affect signaling through
these cytokines. Similarly, IL-22 is a member of the IL-10 family thought to signal through Tyk2, but its contribution to the patient’s disease is
unknown.that resulted in a premature termination codon and
absence of Tyk2 protein. The patient exhibited diverse
symptoms, demonstrating the nonredundant functions
of this Jak in signaling via several receptors (Figure 1).
Comparisons of cytokine responsiveness in immune
cells from the human Tyk2-deficient patient and
Tyk2-deficient mice are in some respects predictable.
In general, though, the authors show that Tyk2 defi-
ciency has more profound consequences in human
cells than would be expected from studies in murine
cells.
First, the patient had increased susceptibility to viral
infections, pointing to the criticality of Tyk2 in transmit-
ting signals from the IFN-a and -b receptor (IFNAR).
This is consistent with the documented role of Tyk2
in mediating IFN signals; however, Tyk2 deficiency
has more dramatic effects in human cells than in
mouse cells. IFN-a-induced phosphorylation of other
relevant signaling molecules, such as Jak1 and Stat1,
was completely abrogated in the human Tyk2-deficient
cells, whereas this treatment induced substantial
residual phosphorylation of these proteins in the Tyk2-
deficient mice (Karaghiosoff et al., 2000; Shimoda et al.,
2000). Additionally, original studies using mutant hu-
man cell lines argued for a role of Tyk2 in the proper
trafficking of IFNAR1 to the plasma membrane. Consis-
tent with this observation, human Tyk2 deficiency leads
to decreased surface expression of IFNAR1—this, too,
is different from the mouse, where there are normal
levels of IFNAR1 and 2 surface expression despite
Tyk2 deficiency (Karaghiosoff et al., 2000; Shimoda
et al., 2000).
The patient also suffered from atypical mycobacterial
infections, and deficits in the IL-12 and IFN-g axis are
known to result in susceptibility to these pathogens
(Reichenbach et al., 2001). The authors show that
Tyk2 is critical for IL-12 signaling in humans. Lack of
IL-12 signaling resulted in impaired T helper 1 differen-
tiation and IFN-g production. IFN-g treatment is effec-
tive for some patients, but whether Tyk2-deficient
patients would be responsive is uncertain becauseabsence of this kinase also evidently impairs IFN-g sig-
naling. This appears to be due to a reduction in total
Stat1 levels rather than impaired proximal IFN-g signal-
ing, which relies on Jak1 and Jak2. Thus, impairment in
IFN-g signaling is another contributor to impaired host
defense, which may have important consequences with
respect to therapy in these patients.
Another feature of this patient’s disease was atopic
dermatitis, elevated levels of immunoglobulin (Ig) E,
and exaggerated in vitro T helper (Th)2 differentiation
with increased production of IL-5 and IL-13. The clinical
manifestations are consistent with defective IL-12
signaling in that impaired Th1 differentiation with skew-
ing toward Th2 polarization would be expected in this
setting. More recently, though, it has been recognized
that IL-12 and IL-23 share ligand and receptor subunits,
and both activate Tyk2. IL-23 is thought to be important
in maintenance of IL-17-producing cells. IL-23 and IL-17
are important in the pathogenesis of autoimmune dis-
ease and host defense against extracellular bacteria.
Previous studies in mice pointed to a key role of Tyk2
in IL-23 signaling (Shaw et al., 2003). Interestingly, the
Tyk2-deficient patient also suffered from skin ab-
scesses. It is possible that one aspect of the pathogen-
esis of this immunodeficiency is the failure to produce
IL-17. This was not explored by the authors but is clearly
an area worthy of future study. IL-23 also induces the
production of IL-22, which in turn induces the produc-
tion of defensins in skin; this too may contribute to the
patient’s disease.
IL-10 is a critical anti-inflammatory cytokine, and
Il102/2mice suffer from fatal, systemic autoimmune dis-
ease. Tyk2 is also activated by IL-10, and Tyk2 defi-
ciency affects the ability to generate and respond to
IL-10 (Shaw et al., 2006). Studies of the Tyk2 patient
cells also showed defective IL-10 signaling. Why then
did the patient not also have autoimmune disease? It
is tempting to speculate that impaired IL-12 and IL-23
signaling might attenuate manifestations of autoim-
munity; clearly, this aspect of the patient’s disease is
worthy of further consideration. Additionally, a number
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697of other cytokines are in the IL-10 family (IL-19, IL-20, IL-
22, and IL-26), and the extent to which they depend
upon Tyk2 was not evaluated.
A difference noted in the present study versus
what was seen in cells from Tyk2-deficient mice is re-
sponsiveness to IL-6. IL-6 signaling in the mouse ap-
pears to be Tyk2-independent, whereas IL-6 signaling
in the patient cells was partially Tyk2 dependent. This
is of interest because IL-6 utilizes the gp130 receptor
chain, which is common to a large family of cytokines
including IL-6, IL-11, IL-27, IL-31, oncostatin M (OSM),
ciliary neurotrophic factor, cardiotrophin-1, cardiotro-
phin-like cytokine, and leukemia inhibitory factor (LIF).
More studies will be needed to determine which, if
any, other gp130 cytokine members are affected by
Tyk2 deficiency and whether these deficits are clinically
relevant.
In conclusion, the ‘‘experiment of nature’’ described
herein clearly establishes the critical role of Tyk2 in hu-
mans, and the signaling defects found correlate well with
the clinical presentation. How common is this disorder?
Apparently, not very common; in fact, the authors care-
fully point out that this genetic lesion may be the determi-
nant for only a subset of patients with recessive HIES.
Notably, the autosomal-dominant form of HIES is asso-
ciated with skeletal abnormalities, and it is clear that this
is a distinct clinical entity. However, the findings are also
of potential interest with respect to the development of
immunosuppressive drugs. Because Jak3 deficiency is
associated with profound immunodeficiency, consider-
able effort has been exerted in developing a clinically
useful Jak3 antagonist (Changelian et al., 2003). Such
a drug has been developed and is currently being stud-
ied in clinical trials in the setting of transplant rejection,
rheumatoid arthritis, and psoriasis. Given that the devel-
opment of a selective Jak antagonist is feasible and
given the emerging information on the IL-23 and IL-17
axes in immune-mediated disease, development of
a Tyk2 inhibitor appears to be a reasonable strategy.Immunity 25, November 2006 ª2006 Elsevier Inc. DOI 10.1016/j.immuni.20
Thymus Exclusivity:
All the Right Conditions
for T Cells
A fraction of primitive ‘‘lymphoid’’ precursors retain
plasticity for myeloid differentiation. In this issue of
Immunity, Laiosa et al. describe that Notch-Delta
signals can protect thymic precursors from repro-
gramming into the myeloid lineage, antagonizing the
enforced myeloid transcription factors such as PU.1
and C/EBPa.
For efficient T cell production, primitive hematopoietic
progenitors require the influence of the thymic micro-
environment. However, the progenitor population thatLike all other immunosuppressive drugs, a Tyk2 inhibitor
would not be without risks. Analysis of Tyk2-deficient
patients can give clues as to what to expect in humans
treated with a Tyk2 antagonist.
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directly seeds the thymus is still controversial (Traver
and Akashi, 2004). In the bone marrow, at least three in-
dependent ‘‘lymphoid’’ progenitor subsets are respon-
sible for seeding the thymus to develop T cells. These
include IL-7Ra+Sca-1loc-Kitlo common lymphoid pro-
genitors (CLPs), IL-7Ra+pTa+B220+CD192c-Kit2 cells
(CLP-2), and IL-7Ra2RAG1+Sca-1+c-Kit+ earliest lym-
phocyte progenitors (ELPs), all of which possess robust
T cell potential in vivo (Figure 1; Traver and Akashi, 2004).
Although CLPs do not generate granulocyte-monocyte
(GM) lineage cells, RAG1-expressing ELPs still possess
a minor GM potential. Immediately after intravenous
transplantation of whole bone marrow cells into irradi-
ated hosts, a substantial fraction of thymic immigrants
contains progenitors with GM potential (Mori et al.,
2001). In the steady-state thymus, the CD252CD44+c-
Kit+ early thymic progenitor subset that should contain
